VOR vs XOMA
VOR: Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers. XOMA: A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights across a diversified 120+ asset portfolio spanning oncology, rare disease, and specialty therapeutics.
Side-by-side fundamentals
| Metric | VOR | XOMA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.51 | $40.17 | |
| Market cap as of 2026-07-23 | $1.1B | $710M | |
| P/E as of 2026-07-23 | n/a | 21.00 | |
| PEG as of 2026-07-23 | -0.00 | n/a | |
| Net margin as of 2026-07-23 | n/a | +69.6% | |
| Gross margin as of 2026-07-23 | n/a | +100.0% | |
| Operating margin as of 2026-07-23 | n/a | +61.3% | |
| ROE as of 2026-07-23 | -142.1% | +32.4% | XOMA higher |
| ROA as of 2026-07-23 | -261.2% | +13.1% | XOMA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.91 | VOR lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +13.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +105.3% | |
| Dividend yield as of 2026-07-23 | n/a | +0.8% | |
| Beta as of 2026-07-23 | 1.60 | 0.88 | |
| 1-year return as of 2026-07-22 close | -51.1% | +48.0% | XOMA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.